 |
Dedicated to precision medical services and product development |
|
|
|
|
| |
|
|
|
|
PDX models |
| We have established 1200+ high-quality PDX models of more than 40 common cancer types, including a series of special drug-resistant PDX models such as EGFR single / double / triple mutations in lung cancer, triple negative breast cancer, KRAS, HER2, ALK fusion, ROS1 fusion, NTRK fusion, etc . All these models have been profiled by NGS + RNA seq following the highest international standards of PDX Consortium. Each passage of the PDX models were re-evaluated by board certified pathologist at CAP certified clinical testing lab (LIWEN)
Read More> |
|
|
|
|
|
|
CDX models |
|
|
| Xenograft models established by transplanting in vitro cultured cell lines into immunodeficient mice. The platform is currently widely used in the drug research and the initial drug screening. With more than 100 cell lines, LIDE Biotech has extensive experience in drug discovery and development in CDX models. Read More> |
|
|
|
| |
|
|
|
|
|
|
Immuno-Oncology platform |
LIDE has extensive experience on Syngeneic Models for Immuno-Oncology drug targets. Read More>
|
|
|
PBMC humanized mouse model is playing key role on pharmacology screening of IO drug candidate. Over the past years, LIDE has developed a serial of PBMC reconstitution humanized mouse models to evaluate the IO target for T Cell, Dendric Cell, Macrophage etc. We have experience on efficacy test of small molecule, antibody, CAR-T and Oncolytic Virus on our humanized mouse models.
Read More> |
| |
|
| |
|
|
|
|
Co-clinical trial platform |
|
|
For a government sponsored Medical Big Data project, 100 Investigator Initiated Trials (II-T) have been carried out with 100+ patient per trial to evaluate the correlation of MiniPDX with clinic result. The fast turnaround (7 days) in vivo efficacy test with fresh patient tumor samples offered unique tool to support new drug R&D. Many pharma companies are joining these MiniPDX Mouse Trial to identify clinical indication for their drug candidate or for patient stratification. Some companies also add MiniPDX in the exploratory arm of their Phase I/IIa clinical trials. This kind of Co-Clinical Trial offering valuable information in Biomarker Driven Clinical Trials.
Read More> |
|
|
| |
|
|
|
|
|
|
New Technology Platform |
| To help fine analysis of cell subsets in tumor immune microenvironment and discovery of biomarkers, LIDE Biotech has established a series of new technology platforms, including detection services of single cell proteome and transcriptome sequencing (10X Genomics and BD Rhapsody), single cell mass spectrometry flow (CyTOF) , imaging mass spectrometry flow (IMC) and Simoa (Single-molecule Array) digital ELASA technology.Read More> |
| |
|
| |
|
|
| |
| About LIDE Biotech |
|
| |
Shanghai LIDE Biotechnology Co., Ltd. ("Shanghai LIDE"), is committed to translational medicine and precision medical research of cancer, provide drug treatment guides to physicians, and proposing personalized treatment plans. The company owns AAALAC accredited SPF level animal centers and world-class equipment. Shanghai LIDE has two wholly-owned subsidiaries, "Xi'an LIDE Biotechnology Co., Ltd." and "Shanghai LIWEN Diagnostics Co., Ltd." (hereinafter referred to as "Shanghai LIWEN") both with qualification of clinical testing laboratory.
|
| |
| |
|
 |
TEL: 400-821-0176 |
 |
 |
E-mail: CRO@lidebiotech.com |
 |
Add: 3F, Building 77-78, 887 Zuchongzhi Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China, 201203. |
| |
|
| |
Get more clinical information，click on the URL below.
http://www.lidebiotech.com/ |
| |
|
|
| |
|